Plasma Cell Neoplasms

This refers to cancers that grow from plasma cells. Plasma cells are a type of white blood cell that normally fights infection. When they grow out of control, it forms a plasma cell neoplasm.

Condition

What people with Plasma Cell Neoplasms report

Every report comes from a Lived member, sent anonymously.

Have you tried Revlimid (Lenalidomide) for Plasma Cell Neoplasms?

NameHow it went

About Plasma Cell Neoplasms

What It Is

Plasma cell neoplasms are a group of conditions in which one line of abnormal plasma cells multiplies out of control. Plasma cells are white blood cells, mostly found in the bone marrow, that normally make antibodies to fight infection. When a single abnormal plasma cell copies itself over and over, all of its copies make the same antibody, called M protein (monoclonal protein). It does not help fight infection, but it can be measured in the blood or urine, which is how many of these conditions are found. The group runs from harmless-looking to serious. Monoclonal gammopathy of undetermined significance (MGUS) is the most common and is not cancer: abnormal cells make up a small share of the marrow, there are usually no symptoms, and it is often discovered by chance on a routine blood test. Smoldering myeloma has more abnormal cells or protein but still causes no damage. A plasmacytoma is a single tumor of plasma cells, in a bone or less often in soft tissue such as the throat or sinuses. Multiple myeloma is a blood cancer in which abnormal plasma cells fill the bone marrow and damage bone in many places. In myeloma, the abnormal cells crowd out the marrow's normal work and weaken bone. That explains its typical effects: bone pain (often in the back or ribs) and fractures, tiredness from anemia (too few red blood cells), frequent infections, kidney damage and high calcium in the blood. Some plasma cell neoplasms also cause amyloidosis, in which pieces of the abnormal antibody build up in organs such as the heart, kidneys and nerves and stiffen them. Because the outlook ranges from simple monitoring to long-term cancer care, the specific type matters far more than the umbrella name.

Causes & Risk Factors

In most people no cause can be found. Plasma cell neoplasms are most common in middle age and later life, and most people diagnosed with multiple myeloma are 65 or older. Myeloma is more than twice as common in Black people as in White people and slightly more common in men. Other recognized risk factors are excess body weight, exposure to radiation or certain chemicals, a parent or sibling with myeloma, and already having MGUS or a plasmacytoma. MGUS is the clearest link. It raises the chance of later developing myeloma or a related disease, yet most people with MGUS never do: about 1% a year progress, and the risk is higher when the M protein level is high. Family history works the same way. It raises risk, but most people with myeloma have no affected relatives, and none of these factors means a person will develop the disease.

How It's Diagnosed

These conditions are often first suspected from routine blood work, such as high total protein, anemia, high calcium or reduced kidney function, or from a fracture or an X-ray showing thinned or damaged bone. Specialized blood and urine tests (protein electrophoresis, immunofixation and a free light chain test) then show whether a single abnormal antibody is present, which kind it is and how much there is. That amount becomes a marker that is measured again and again to track the condition over time. A bone marrow biopsy, in which a needle takes a small sample from the back of the hip bone after the skin is numbed, shows what share of the marrow is abnormal plasma cells and which genetic changes they carry. Imaging such as whole-body low-dose CT, PET-CT or MRI looks for bone damage that ordinary X-rays can miss. The type is decided from these results together. MGUS means abnormal plasma cells make up less than 10% of the marrow and there is no damage to bones, kidneys or blood counts. Myeloma is diagnosed when abnormal cells are causing that damage, or when tests show features that predict it soon, such as abnormal plasma cells making up 60% or more of the marrow. Smoldering myeloma falls in between. Myeloma is then staged (stage I to III) from two blood proteins, beta-2-microglobulin and albumin, along with certain chromosome changes and LDH, an enzyme that rises with more active disease. Higher stages suggest more disease and a less favorable outlook, which helps guide treatment.

Treatment Options

Treatment depends on the type. MGUS and smoldering myeloma are usually monitored rather than treated, with blood tests at regular intervals to see whether the M protein is rising and checks for new symptoms. For some people with high-risk smoldering myeloma, specialists may discuss starting treatment early: in a recent trial, daratumumab delayed progression to active myeloma compared with watchful waiting. A single plasmacytoma is usually treated with radiation to the tumor, which can sometimes cure it, though a plasmacytoma in bone often later becomes myeloma, so follow-up continues. Active multiple myeloma is treated with combinations of medicines, usually in phases. An initial phase (induction) brings the disease under control. People who are fit enough may then have high-dose chemotherapy followed by a transplant of their own previously collected blood stem cells, aimed at killing myeloma cells that remain after induction; the stem cells then rebuild the marrow. Long-term maintenance treatment then helps keep the disease quiet. Fitness, not age alone, decides transplant: people under 65 are usually candidates, people over 75 usually are not, and in between it depends on overall health. The usual building blocks are lenalidomide (Revlimid), an immunomodulatory pill that acts on myeloma cells and the immune system; bortezomib (Velcade), a proteasome inhibitor that blocks the cell's protein disposal system so myeloma cells clog and die; daratumumab (Darzalex), an antibody that marks myeloma cells for destruction; and a steroid such as dexamethasone. Each has trade-offs worth weighing. Lenalidomide and the related drugs thalidomide and pomalidomide can cause severe birth defects, so they are dispensed only through programs that require pregnancy testing and contraception, and they raise the risk of blood clots, so most people also take aspirin or another blood thinner. Bortezomib commonly causes nerve damage felt as numbness, tingling or burning in the hands and feet, which is managed by adjusting the dose. Myeloma usually returns at some point, and there are further options when it does: a different drug combination, CAR T-cell therapy (the person's own immune cells reprogrammed in a lab to attack myeloma) and bispecific antibodies such as teclistamab, which link immune cells directly to myeloma cells. These newer treatments can work even after many earlier treatments have stopped working, but they often cause cytokine release syndrome, a body-wide inflammatory reaction triggered by the activated immune cells, and serious infections, so they are given at specialized centers. Clinical trials are a reasonable option at any stage. Supportive care runs alongside all of this: bone-strengthening drugs (bisphosphonates such as zoledronic acid, or denosumab) to reduce fractures and bone pain, radiation for painful bone lesions, vaccinations and sometimes antibody infusions to prevent infection, and plasmapheresis, a procedure that filters excess protein out of blood that has become too thick.

What to Expect

The outlook differs more across this group than within most diagnoses. Most people with MGUS live with it for the rest of their lives without it becoming a problem. For them, the condition mainly means periodic blood tests and checkups to make sure the protein level and blood counts stay stable. A solitary plasmacytoma can sometimes be cured with treatment, but it needs ongoing checks because some progress to myeloma. Multiple myeloma is highly treatable but rarely curable. It tends to follow a cycle: treatment, a period of remission that can last years, a return of the disease, and another line of treatment. Results have improved markedly as newer drugs have arrived, and half of people in recent series now live more than 10 years after diagnosis. Individual outlook still varies widely with stage, the myeloma's genetic features, kidney function and how well the first treatment works. Living with myeloma usually means regular clinic visits, frequent blood tests to follow the M protein and blood counts, and periodic scans. Fatigue, bone pain and a higher risk of infection are common, both from the disease and from long-term treatment. Treatment is often continued for long stretches rather than given once, so the balance between control of the disease and side effects is revisited over time with the care team.

When to Seek Help

Arrange a medical visit for bone pain that does not settle, especially in the back or ribs, bones that break easily, frequent infections, easy bruising or bleeding, or ongoing unexplained tiredness. If you already have MGUS or smoldering myeloma, keep to your monitoring schedule and report new symptoms like these between checks. During treatment, call your care team promptly for a fever of 100.5 F (38 C) or higher, chills or other signs of infection, since infections can become serious quickly when defenses are weakened. Call promptly too for signs of high calcium: extreme thirst, urinating much more than usual, constipation, or unusual drowsiness or confusion. Get emergency care right away for sudden severe back pain with new numbness or weakness in the legs, which can mean a weakened vertebra has collapsed onto the spinal cord. The same applies to slurred speech or weakness on one side of the body, which can happen when excess protein makes the blood too thick.

Questions to Ask Your Doctor

  1. 1.Which type of plasma cell neoplasm do I have, and what do my test results suggest about how likely it is to progress?
  2. 2.If you recommend monitoring for now, how often will I be tested and what changes would lead us to start treatment?
  3. 3.Am I a candidate for a stem cell transplant, and how would treatment differ if I am not?
  4. 4.What are the main trade-offs of the treatments you are recommending, and how will we watch for side effects such as blood clots, nerve damage or infections?
  5. 5.What can I do to protect my bones and lower my risk of infection, and would a clinical trial make sense for me?

Last reviewed • Oct 2026

Educational content, not medical advice.